AccessibilityHelpAbout Us
Medite Cancer Diagnostics logo

Medite Cancer Diagnostics(OTC) MDIT

Market Cap$8.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)-100%
5 Year-99%
1 Year-98%
1 Month+0%
$0.00
+0.00%
+0.00Today
Medite Cancer Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-04
Medite Cancer Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-03
1 month+0%USD 0.002026-08-03
3 month+0%USD 0.002026-06-02
Year to date+0%USD 0.002025-12-18
1 year-98%USD 0.012025-09-02
3 year+0%USD 0.002023-09-05
5 year-99.38%USD 0.022021-09-03
Since inception-100%USD 100.001998-12-07

Medite Cancer Diagnostics Financials at a Glance

Market Cap

$8.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-16.48 (Low)

Price

$0.00

Volume

1

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Feb 26, 2025

MDIT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medite Cancer Diagnostics

Medite Cancer Diagnostics, Inc. is a medical technology company focused on developing, manufacturing, and marketing molecular biomarkers and medical devices for cancer detection and diagnosis. The company serves histology and cytology laboratories globally, providing innovative solutions for cancerous and precancerous conditions.

Products and Services
  • USE 33, an ultrasonic decalcification instrument for controlled processing
  • SoftKit device for self-collection of female health samples
  • Robotic multi-staining systems and tissue sectioning microtomes
Growth Outlook
  • Expanding product offerings to meet increasing global cancer diagnostics demand
  • Strategic partnerships in Europe and North Africa to enhance market reach
  • Focus on innovative technologies to improve diagnostic accuracy and efficiency
Financial Highlights
  • Market capitalization stands at approximately $8,672
  • Current ratio of 0.92 indicates liquidity challenges
  • Price-to-sales ratio of 0.0013 suggests undervaluation potential
Medite Cancer Diagnostics, Inc. operates in a critical sector, addressing the growing need for effective cancer diagnostics. The company's diverse product range, including advanced tissue processing instruments and self-collection devices, positions it well within the healthcare industry. With a focus on innovation and strategic partnerships, Medite aims to enhance its market presence and drive growth. Recent financial metrics indicate a market capitalization of approximately $8,672, reflecting the company's current valuation. The current ratio of 0.92 suggests potential liquidity challenges, which may impact operational flexibility. However, the low price-to-sales ratio of 0.0013 may indicate an opportunity for investors, suggesting that the stock could be undervalued relative to its revenue generation capabilities. Overall, Medite Cancer Diagnostics, Inc. presents a compelling case for potential investors interested in the healthcare sector, particularly in the area of cancer diagnostics. The company's commitment to innovation and strategic growth initiatives may provide a pathway for future success.
AI Generated • Aug 29, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Headquarters

Orlando, FL 32832, US

MDIT Financials

Key Financial Metrics (TTM)

Gross Margin

-1.92%

Operating Margin

-95.11%

Net Income Margin

-99.97%

Return on Equity

-98.90%

Return on Capital

-58.02%

Return on Assets

-42.69%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

86.20M

Volume

1

Avg. Volume

0.508

Financials (TTM)

Gross Profit

-$131.00K

Operating Income

-$6.48M

EBITDA

-$6.19M

Operating Cash Flow

-$2.59M

Capital Expenditure

-$134.00K

Free Cash Flow

-$2.72M

Cash & ST Invst.

$490.00K

Total Debt

$5.39M

Medite Cancer Diagnostics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$8.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CEVECeres Ventures, Inc.
$0.00+0.00%
RCARRenovaCare, Inc.
$0.00+0.00%
ASFXAmerican Scientific Resources, Incorporated
$0.00+0.00%
SDCCQSmileDirectClub Inc Class A
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.55-0.04%
INTCIntel
$106.24+0.02%
NOKNokia
$10.76+0.01%
NVDANvidia
$223.67-0.01%

Questions About MDIT

What is the current price of Medite Cancer Diagnostics?

Medite Cancer Diagnostics is trading at $0.00 per share.

What is the 52-week range for Medite Cancer Diagnostics?

Over the past 52 weeks, Medite Cancer Diagnostics has traded between $0.00 and $0.01.

How much debt does Medite Cancer Diagnostics have?

Medite Cancer Diagnostics total debt is unavailable.

How much cash does Medite Cancer Diagnostics have on hand?

Medite Cancer Diagnostics does not have cash on hand data available.

What is Medite Cancer Diagnostics’s dividend yield?

Medite Cancer Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services